Not only the miracle medicine for weight loss! Novo Nordisk's search for the development of "obesity prevention drugs" is still in its early stages of research
六月清晨搅
发表于 2023-12-6 18:32:09
296
0
0
While pharmaceutical giants are still fiercely competing over GLP-1 weight loss drugs, Danish pharmaceutical giant Novo Nordisk has already set its sights on developing drugs to prevent obesity.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- The US Senate questions whether the pricing of the "weight loss miracle drug" is too high. Nuo and Nuo De respond that lowering the price is useless
- Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
- Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Lai Lai scares, Novo Nordisk saves the scene! The market prospects of weight loss drugs still make many players salivate
- Novo Nordisk: All regulatory delivery conditions for Novo Nordisk's $16.5 billion acquisition of Contante have been met
- Novo Nordisk invests 8.5 billion Danish kroner to build new production facility in Odense, Denmark
- Novo Nordisk's pre-market decline narrows to 20%
